AstraZeneca PLC (AZN)
NYSE: AZN · Real-Time Price · USD
192.01
+2.11 (1.11%)
At close: Mar 16, 2026, 4:00 PM EDT
192.51
+0.50 (0.26%)
After-hours: Mar 16, 2026, 7:19 PM EDT
AstraZeneca Employees
AstraZeneca had 95,100 employees as of December 31, 2025. The number of employees increased by 2,200 or 2.37% compared to the previous year.
Employees
95,100
Change (1Y)
2,200
Growth (1Y)
2.37%
Revenue / Employee
$617,655
Profits / Employee
$107,518
Market Cap
595.59B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 95,100 | 2,200 | 2.37% |
| Dec 31, 2024 | 92,900 | 3,000 | 3.34% |
| Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
| Dec 31, 2022 | 83,500 | 400 | 0.48% |
| Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
| Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
| Dec 31, 2019 | 70,600 | 6,000 | 9.29% |
| Dec 31, 2018 | 64,600 | 3,500 | 5.73% |
| Dec 31, 2017 | 61,100 | 1,400 | 2.35% |
| Dec 31, 2016 | 59,700 | -1,800 | -2.93% |
| Dec 31, 2015 | 61,500 | 4,000 | 6.96% |
| Dec 31, 2014 | 57,500 | 6,000 | 11.65% |
| Dec 31, 2013 | 51,500 | -200 | -0.39% |
| Dec 31, 2012 | 51,700 | -5,500 | -9.62% |
| Dec 31, 2011 | 57,200 | -3,800 | -6.23% |
| Dec 31, 2010 | 61,000 | -1,700 | -2.71% |
| Dec 31, 2009 | 62,700 | -2,300 | -3.54% |
| Dec 31, 2008 | 65,000 | -2,400 | -3.56% |
| Dec 31, 2007 | 67,400 | 600 | 0.90% |
| Dec 31, 2006 | 66,800 | 1,500 | 2.30% |
| Dec 31, 2005 | 65,300 | 1,100 | 1.71% |
| Dec 31, 2004 | 64,200 | 1,600 | 2.56% |
| Dec 31, 2003 | 62,600 | 3,400 | 5.74% |
| Dec 31, 2002 | 59,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Pfizer | 75,000 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
| Eli Lilly and Company | 50,000 |
AZN News
- 16 hours ago - AstraZeneca's Imfinzi Gets EU Approval for Treatment of Early Gastric Cancer - WSJ
- 4 days ago - Abivax (ABVX) Shares Surge Amid Denial of AstraZeneca Takeover Report - GuruFocus
- 4 days ago - AZN Stock Experiences Slight Dip in Morning Trading - GuruFocus
- 4 days ago - AstraZeneca (AZN) Refutes Takeover Speculation - GuruFocus
- 4 days ago - AstraZeneca (AZN) Obtains Exclusive Negotiation Period with Abivax - GuruFocus
- 4 days ago - AstraZeneca (AZN) Engages in Exclusive Takeover Talks with Abivax - GuruFocus
- 4 days ago - AstraZeneca (AZN) Enters Exclusive Agreement Boosting Abivax Shares - GuruFocus
- 4 days ago - Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline - Benzinga